ITEM 7.01 REGULATION FD DISCLOSURE
On January 21, 2020, Zymeworks issued a press release announcing the filing of a
preliminary prospectus supplement in connection with the issuance and sale of
4,924,729 of the Company's common shares and in lieu of common shares, to a
certain investor, pre-funded warrants to purchase up to 1,075,271 common shares
(the "Offering"), which was filed with the Canadian securities regulatory
authorities in Canada on the System for Electronic Document Analysis and
Retrieval ("SEDAR") at www.sedar.com (the "Launch Press Release"). Additionally,
on January 22, 2020, Zymeworks issued a press release announcing the pricing of
the Offering, which was filed with the Canadian securities regulatory
authorities in Canada on SEDAR (the "Pricing Press Release"). On January 24,
2020, copies of the Launch Press Release and the Pricing Press Release were
furnished to the Securities Exchange Commission (the "SEC") on a Form 8-K.
Subsequently, on January 27, 2020, Zymeworks issued a press release announcing
the closing of the Offering and the exercise in full of the underwriters'
over-allotment option to purchase 900,000 additional shares, which was filed
with the Canadian securities regulatory authorities in Canada on SEDAR (the
"Closing Press Release"). A copy of this press release is attached as Exhibit
99.1 hereto.
The information provided under this Item (including Exhibit 99.1, attached
hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such a filing.
ITEM 8.01 OTHER EVENTS
On January 27, 2020, Zymeworks filed a material change report regarding the
launch, pricing and closing of the Offering, as described in the Launch Press
Release, the Pricing Press Release and the Closing Press Release with the
Canadian securities regulatory authorities. A copy of this material change
report is attached as Exhibit 99.2 hereto.
A copy of the opinion of Blake, Cassels & Graydon LLP relating to the legality
of the securities issuable under the underwriting agreement (filed as an Exhibit
to Zymeworks' Current Report on Form 8-K filed on January 24, 2020) is filed as
Exhibit 5.1 to this Current Report on Form 8-K and is also incorporated by
reference into Zymeworks' automatic shelf registration statement on Form S-3ASR
(No. 333-234517) previously filed with the SEC.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
Exhibit No. Description
5.1 Legal Opinion of Blake, Cassels & Graydon LLP
99.1 Press Release dated January 27, 2020.
99.2 Material Change Report dated January 27, 2020.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses